NACE 84309 in Brussel · BE. Official registry identity, filed financial evidence and a rounded indicative valuation range on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for SEFOCAM combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
SEFOCAM is a business in NACE sector 84309 based in Brussel, Belgium. The company was founded in 2002, incorporated as a Vereniging zonder winstoogmerk.
SEFOCAM is listed in Belgian Crossroads Bank for Enterprises (KBO) under registry number 0478924632 and VAT number BE0478924632. This profile consolidates Kbo Open Data, NBB/CBSO annual accounts into one indexable company dossier.
Within the Belgian NACE 84309 cluster, public-record data is filed annually via the national company registry.
Across the 2024-2025 window revenue has stayed broadly flat, moving from €944,096 to €927,980. EBITDA for 2025 comes in at €27,400.
An indicative valuation band is available for SEFOCAM, based on filed company accounts. A free account lets the visitor refine it with current data and build a five-year outlook.
The most recent annual filing covers 2025 (period end 2025-12-31).
If you are researching SEFOCAM for acquisition, investment, or due-diligence purposes, this page consolidates its firmographics, multi-year filings, and an indicative valuation into a single, citation-ready view.
Public regulator-filed figures across 2 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Dec 2025 | €927,980 | €27,400 | €2,891,929 | €2,747,192 | - |
| 202431 Dec 2024 | €944,096 | €27,585 | €3,057,111 | €2,708,292 | - |
SEFOCAM was founded in 2002 and is registered with Belgian Crossroads Bank for Enterprises (KBO), incorporated as a Vereniging zonder winstoogmerk.
SEFOCAM is registered under NACE 84309: NACE 84309. That places the business within the Belgian cluster for this activity.
According to the company registry, SEFOCAM is based in Brussel, BE.
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-12-31), publicly available via Belgian Crossroads Bank for Enterprises (KBO).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for SEFOCAM may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
